谷氨酰胺与肿瘤代谢及其在核医学中的应用

doi:10.3760/cma.j.issn.1673-422X.2015.02.011

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (2): 122-125.doi: 10.3760/cma.j.issn.1673-422X.2015.02.011

谷氨酰胺与肿瘤代谢及其在核医学中的应用

刘菲,朱华,林新峰,罗政,李囡,杨志

100142北京大学肿瘤医院暨北京市肿瘤防治研究所核医学科恶性肿瘤发病机制及转化研究教育部重点实验室

出版日期:2015-02-08 发布日期:2015-02-02
通讯作者: 杨志 E-mail:pekyz@163.com
基金资助:
国家自然科学基金（81371592、81172083、81071198）；北京市自然科学基金（7132040）

Glutamine and tumor metabolism and their applications in nuclear medicine

Liu Fei, Zhu Hua, Lin Xinfeng, Luo Zheng, Li Nan, Yang Zhi

Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Beijing 100142, China

Online:2015-02-08 Published:2015-02-02
Contact: Yang Zhi E-mail:pekyz@163.com

摘要/Abstract

摘要： 许多肿瘤依赖谷氨酰胺（Gln）供能，Gln代谢被认为是除Warburg效应之外又一重要的肿瘤细胞能量代谢特征之一。以正电子发射计算机断层扫描（PET）为代表的核医学分子示踪技术为肿瘤的早期诊断和预后提供了很好的手段，利用PET显像技术可以无创地探测肿瘤Gln代谢区域，为优化肿瘤诊断和治疗方案提供了新策略。

关键词: 谷氨酰胺, 肿瘤, 核医学, 分子探针

Abstract: Many tumors depend on glutamine for energy. Glutamine metabolism is recognized as a distinctive feature in addition to Warburg effect in tumors. Nuclear medicine molecular tracer techniques represented by positron emission tomography (PET) provide a good means for early diagnosis and prognosis of tumors. PET imaging can detect glutamine metabolism region in tumors noninvasively, which can provide new diagnosis and therapeutics for glutamineaddicted tumors.

Key words: Glutamine, Neoplasms, Nuclear medicine, Molecular probes

刘菲,朱华,林新峰,罗政,李囡,杨志. 谷氨酰胺与肿瘤代谢及其在核医学中的应用[J]. 国际肿瘤学杂志, 2015, 42(2): 122-125.

Liu Fei, Zhu Hua, Lin Xinfeng, Luo Zheng, Li Nan, Yang Zhi. Glutamine and tumor metabolism and their applications in nuclear medicine[J]. Journal of International Oncology, 2015, 42(2): 122-125.

参考文献

［1］ Koppenol WH, Bounds PL, Dang CV. Otto Warburg′s contributions to current concepts of cancer metabolism［J］. Nat Rev Cancer, 2011, 11(5): 325-337. ［2］ DeBerardinis RJ, Cheng T. Q′s next: the diverse function of glutamine in metabolism, cell biology and cance［J］. Oncogene, 2010, 29(3): 313-324. ［3］ Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology physiology, and clinical opportunities［J］. J Clin Invest, 2013, 123(9): 3678-3684. ［4］ Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer［J］. Trends Biochem Sci, 2010, 35(8): 427-433. ［5］ Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy［J］. Cell, 2009, 136(3): 521-534. ［6］ Jewell JL, Russell RC, GuanKL. Amino acid signaling upstream of mTOR［J］. Nat Rev Mol Cell Biol, 2013, 14(3): 133-139. ［7］ Csibi A, Fendt SM, Li C, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4［J］. Cell， 2013, 153(4): 840-854. ［8］ Qu W, Oya S, Lieberman BP, et al. Preparation and characterization of L［511C］glutamine for metabolic imaging of tumors［J］. J Nucl Med, 2012, 53(1): 98-105. ［9］ Gao P, Tchernyshyov I, Chang TC, et al. cMyc suppression of miR23a/b enhances mitochondrial glutaminase expression and glutamine metabolism［J］. Nature, 2009, 458(7239): 762-765. ［10］ Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?［J］. Semin Cancer Biol, 2005, 15(4): 254-266. ［11］ van den Heuvel AP, Jing J, Wooster RF, et al. Analysis of glutamine dependency in nonsmall cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth［J］. Cancer Biol Ther, 2012, 13(12):1185-1194. ［12］ Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell typespecific glutamine independence in breast epithelia［J］. PLoS Genet, 2011, 7(8): e1002229. ［13］ Wang Q, Beaumont KA, Otte NJ, et al. Targeting glutamine transport to suppress melanoma cell growth［J］. Int J Cancer, 2014, 135(5): 1060-1071. ［14］ Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a Kras regulated metabolic pathway［J］. Nature, 2013, 496(7443): 101-105. ［15］ Hassanein M, Hoeksema MD, Shiota M, et al. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival［J］. Clin Cancer Res, 2013, 19(3): 560-570. ［16］ Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation［J］. Cancer Cell, 2010, 18(3): 207-219. ［17］ Robinson MM, McBryant SJ, Tsukamoto T, et al. Novel mechanism of inhibition of rat kidneytype glutaminase by bis2(5 phenylacetamido1,2,4thiadiazol2yl)ethyl sulfide (BPTES)［J］. Biochem J, 2007, 406(3): 407-414. ［18］ Qing G, Li B, Vu A, et al. ATF4 regulates MYCmediated neuroblastoma cell death upon glutamine deprivation［J］. Cancer Cell, 2012， 22(5): 631-644. ［19］ Thornburg JM, Nelson KK, Clem BF, et al. Targeting aspartate aminotransferase in breast cancer［J］. Breast Cancer Res, 2008, 10(5): R84. ［20］ Robey IF, Stephen RM, Brown KS, et al. Regulationof the Warburg effect in earlypassage breast cancer cells［J］. Neoplasia, 2008, 10(8): 745-756. ［21］ Yu EY, Muzi M, Hackenbracht JA, et al. C11acetate and F18 FDG PET for men ith prostate cancer bone metastases: relative findings and response to therapy［J］. Clin Nucl Med, 2011, 36(3): 192-198. ［22］ Levine AJ, PuzioKuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes［J］. Science, 2010，330(6009): 1340-1344. ［23］ Dinkelborg L, Friebe M, Krasikowa RN, et al. ［18F］ labelled Lglutamic acid, ［18F］ labelled glutamine, their derivatives, their use and processes for their preparation: EP, 1923382［P］. 20080521. ［24］ Kung HF, Thompson CB, Qu WC, et al. Single diastereomers of 4fluoroglutamine and methods for their preparation and use: US, WO2011/020018［P］. 20110217. ［25］ Lieberman BP, Ploessl K, Wang L, et al. PET imaging of glutaminolysis in tumors by 18F(2S,4R)4fluoroglutamine［J］. J Nucl Med, 2011, 52(12): 1947-1955. ［26］ Ploessl K, Wang L, Lieberman BP, et al. Comparative evaluation of 18Flabeled glutamic acid and glutamine as tumor metabolic imaging agents［J］. J Nucl Med, 2012, 53(10): 1616-1624.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

谷氨酰胺与肿瘤代谢及其在核医学中的应用

Glutamine and tumor metabolism and their applications in nuclear medicine

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价